Icos COPD agent fails Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Failure of Icos' IC485 in a Phase II chronic obstructive pulmonary disease study is shifting the firm's focus to its "preclinical-stage PDE-4 inhibitors that are more potent and have other characteristics that enhance the probability of clinical success." The clinical-stage PDE-4 inhibitor did not meet the primary endpoint of improved lung function in a 258-patient placebo-controlled study, Icos says March 23...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.